- Home
- INDO vs IFRX Comparison
INDO vs IFRX Comparison
Compare INDO & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDO
- IFRX
- Stock Information
- Founded
- INDO 2018
- IFRX 2007
- Country
- INDO Indonesia
- IFRX Germany
- Employees
- INDO N/A
- IFRX N/A
- Industry
- INDO Oil & Gas Production
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- INDO Energy
- IFRX Health Care
- Exchange
- INDO Nasdaq
- IFRX Nasdaq
- Market Cap
- INDO 45.6M
- IFRX 53.5M
- IPO Year
- INDO 2019
- IFRX 2017
- Fundamental
- Price
- INDO $3.08
- IFRX $1.47
- Analyst Decision
- INDO
- IFRX Strong Buy
- Analyst Count
- INDO 0
- IFRX 5
- Target Price
- INDO N/A
- IFRX $7.40
- AVG Volume (30 Days)
- INDO 412.2K
- IFRX 505.1K
- Earning Date
- INDO 10-24-2025
- IFRX 11-07-2025
- Dividend Yield
- INDO N/A
- IFRX N/A
- EPS Growth
- INDO N/A
- IFRX N/A
- EPS
- INDO N/A
- IFRX N/A
- Revenue
- INDO $2,293,625.00
- IFRX $191,224.00
- Revenue This Year
- INDO N/A
- IFRX N/A
- Revenue Next Year
- INDO N/A
- IFRX $1,216.24
- P/E Ratio
- INDO N/A
- IFRX N/A
- Revenue Growth
- INDO N/A
- IFRX 54.36
- 52 Week Low
- INDO $2.10
- IFRX $0.71
- 52 Week High
- INDO $7.95
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- INDO 52.38
- IFRX 53.45
- Support Level
- INDO $2.94
- IFRX $1.29
- Resistance Level
- INDO $3.06
- IFRX $1.44
- Average True Range (ATR)
- INDO 0.13
- IFRX 0.12
- MACD
- INDO 0.00
- IFRX -0.01
- Stochastic Oscillator
- INDO 35.85
- IFRX 32.43
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.